Abstract:Background: Macrophage accumulation in the vascular wall is a hallmark of atherosclerosis. Studies showed that shifting of oxidized lipids-induced inflammatory macrophages towards an anti-inflammatory phenotype by promoting oxidative metabolism attenuated atherosclerosis progression. Therefore, this study aimed to investigate whether metformin, which has ameliorated atherosclerosis in animal models and clinical trials, modulated oxidized low-density lipoprotein (Ox-LDL) induced inflammatory status in macrophages by regulating cellular oxidative metabolism. Methods: Murine raw264.7 macrophages were incubated with Ox-LDL (50 μg/mL) in the presence or absence of metformin (15 μmol/L) for 24 h. Real-time polymerase chain reaction was used to quantify the transcription of classically activated (M1) pro-inflammatory and alternatively activated (M2) anti-inflammatory markers and mitochondrial DNA copy numbers. Cellular reactive oxygen species (ROS) production and mitochondrial membrane potential were detected by immunofluorescence. Cellular adenosine triphosphate (ATP) synthesis, glucose uptake, and lactic acid production were measured by commercial kit and normalized to cellular lysates. Western blotting analysis was performed to detect the expression of mitochondrial fusion/fission related proteins, enzymes mediating lipid metabolism and signaling pathway of glucose transport. Differences between groups were analyzed using one-way analysis of variance. Results: Metformin improved Ox-LDL-impaired anti-inflammatory phenotype in raw264.7 macrophages as shown by up-regulated transcription of anti-inflammatory markers including interleukin 10 (0.76 ± 0.04 vs. 0.94 ± 0.01, P = 0.003) and Resistin-like molecule alpha (0.67 ± 0.08 vs. 1.78 ± 0.34, P = 0.030). Conversely, Ox-LDL-diminished phosphorylation of Akt was up-regulated by metformin treatment (0.47 ± 0.05 vs. 1.02 ± 0.08, P = 0.040), associated with an improvement of mitochondrial function, characterized by decreased ROS generation (2.50 ± 0.07 vs. 2.15 ± 0.04, P = 0.040), increased lipid oxidation, and elevated cellular ATP production (0.026 ± 0.001 vs. 0.035 ± 0.003, P = 0.020). Moreover, metformin-mediated Akt activation increased Akt substrate of 160 kDa (AS160) phosphorylation (0.51 ± 0.04 vs. 1.03 ± 0.03, P = 0.0041), promoted membrane translocation of glucose transporter 1, and increased glucose influx into the cells (4.78 ± 0.04 vs. 5.47 ± 0.01, P < 0.001). Conclusion: This study suggested that targeting macrophage metabolism with new or existing drugs had therapeutic potential for the prevention and treatment of diabetes-accelerated atherosclerosis.

Microarray analysis of tRNA-derived small RNA (tsRNA) in LPS-challenged macrophages treated with metformin

Transcriptomic and Proteomic Analysis of Potential Therapeutic Target Genes in the Liver of Metformin‑treated Sprague‑Dawley Rats with Type 2 Diabetes Mellitus

Metformin Shows Anti‐inflammatory Effects in Murine Macrophages Through Dicer/microribonucleic Acid‐34a‐5p and Microribonucleic Acid‐125b‐5p

Metformin improved oxidized low-density lipoprotein-impaired mitochondrial function and increased glucose uptake involving Akt-AS160 pathway in raw264.7 macrophages

Metformin Inhibits Porphyromonas Gingivalis Lipopolysaccharide-Influenced Inflammatory Response in Human Gingival Fibroblasts Via Regulating Activating Transcription Factor-3 Expression

Metformin Inhibits Chemokine Expression Through the AMPK/NF-κB Signaling Pathway.

Multi-omics analysis of the lipid-regulating effects of metformin in a glucose concentration-dependent manner in macrophage-derived foam cells

Identification and Validation of Metformin Protects Against PM2.5-induced Macrophages Cytotoxicity by Targeting Toll Like Receptor Pathway

Metformin Alleviates Inflammation Through Suppressing FASN-dependent Palmitoylation of Akt

Metformin Inhibits ROS Production by Human M2 Macrophages via the Activation of AMPK

Effects of inflammatory and anti-inflammatory environments on the macrophage mitochondrial function

Metformin Inhibits Advanced Glycation End Products-Induced Inflammatory Response in Murine Macrophages Partly through AMPK Activation and RAGE/NFκB Pathway Suppression.

Metformin Inhibited Nod-like Receptor Protein 3 Inflammasomes Activation and Suppressed Diabetes-Accelerated Atherosclerosis in Apoe−/− Mice

Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice

Metformin Inhibits Lps-Stimulated Microglial Proliferation And Reduces The Release Of Inflammatory Cytokines

Metformin enhances ATP-stimulated inflammasomeactivation in LPS-primed peritoneal macrophages

Metformin activated AMPK signaling contributes to the alleviation of LPS-induced inflammatory responses in bovine mammary epithelial cells

[Metformin Inhibits THP-1 Macrophage-Derived Foam Cell Formation Induced by Lipopolysaccharide].

Metformin, Macrophage Dysfunction and Atherosclerosis

Long Non-Coding RNA and Mrna Profile Analysis of Metformin to Reverse the Pulmonary Hypertension Vascular Remodeling Induced by Monocrotaline.

Metformin Treatment Modulates Long Non-Coding RNA Isoforms Expression in Human Cells